LXEO
Lexeo Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$320M
5Y Perf.-54.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LXEO vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-32.7%
LXEO vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LXEO | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $320M | $2.57B |
| Revenue (TTM) | $0.00 | $669M |
| Net Income (TTM) | $-105M | $-609M |
| Gross Margin | — | 83.6% |
| Operating Margin | — | -83.9% |
| Total Debt | $10M | $1.28B |
| Cash & Equiv. | $35M | $434M |
LXEO vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LXEO
RARE
| Stock | Nov 23 | May 26 | Return |
|---|---|---|---|
| Lexeo Therapeutics,… (LXEO) | 100 | 45.8 | -54.2% |
| Ultragenyx Pharmace… (RARE) | 100 | 67.3 | -32.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LXEO vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RARE leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Lexeo Therapeutics, Inc. Common Stock is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
LXEO
Lexeo Therapeutics, Inc. Common Stock
The Long-Run Compounder
LXEO is the clearest fit if your priority is long-term compounding.
- -42.1% 10Y total return vs RARE's -59.4%
- 5.1% margin vs RARE's -91.0%
- +94.6% vs RARE's -21.8%
Best for: long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Income Pick
RARE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.42
- Rev growth 20.1%, EPS growth 7.3%, 3Y rev CAGR 22.8%
- Lower volatility, beta 1.42, current ratio 2.48x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs LXEO's -21.6% |
| Quality / Margins | LXEO | 5.1% margin vs RARE's -91.0% |
| Stability / Safety | RARE | Beta 1.42 vs LXEO's 1.98 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | LXEO | +94.6% vs RARE's -21.8% |
| Efficiency (ROA) | RARE | -45.8% ROA vs LXEO's -70.9%, ROIC -89.4% vs -166.2% |
LXEO vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
LXEO vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRARELAGGINGLXEO
LXEOLexeo Therapeutics, I…
2leads
RAREUltragenyx Pharmaceut…
3leads
6 Total Categories
CATEGORYLEADERvs LXEOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LXEO1/1
Valuation MetricsMultiples, price ratios, and targets
RARE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RARE5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
LXEO5/6
Risk & VolatilityBeta, volatility, and downside exposure
RARE2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LXEO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RARE and LXEO operate at a comparable scale, with $669M and $0 in trailing revenue.
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $669M |
| EBITDAEarnings before interest/tax | -$111M | -$536M |
| Net IncomeAfter-tax profit | -$105M | -$609M |
| Free Cash FlowCash after capex | -$107M | -$487M |
| Gross MarginGross profit ÷ Revenue | — | +83.6% |
| Operating MarginEBIT ÷ Revenue | — | -83.9% |
| Net MarginNet income ÷ Revenue | — | -91.0% |
| FCF MarginFCF ÷ Revenue | — | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.9% | -17.2% |
LXEO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $320M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $295M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.88x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.58x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
RARE leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
LXEO delivers a -90.5% return on equity — every $100 of shareholder capital generates $-90 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs LXEO's 2/9, reflecting mixed financial health.
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -90.5% | -6.1% |
| ROA (TTM)Return on assets | -70.9% | -45.8% |
| ROICReturn on invested capital | -166.2% | -89.4% |
| ROCEReturn on capital employed | -85.8% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.08x | — |
| Net DebtTotal debt minus cash | -$25M | $842M |
| Cash & Equiv.Liquid assets | $35M | $434M |
| Total DebtShort + long-term debt | $10M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -754.06x | -14.49x |
RARE leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
LXEO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LXEO five years ago would be worth $5,791 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, LXEO leads with a +94.6% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors LXEO at -16.6% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -39.4% | +10.7% |
| 1-Year ReturnPast 12 months | +94.6% | -21.8% |
| 3-Year ReturnCumulative with dividends | -42.1% | -44.5% |
| 5-Year ReturnCumulative with dividends | -42.1% | -77.2% |
| 10-Year ReturnCumulative with dividends | -42.1% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -16.6% | -17.8% |
LXEO leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
RARE leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RARE is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than LXEO's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 61.7% from its 52-week high vs LXEO's 53.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.98x | 1.42x |
| 52-Week HighHighest price in past year | $10.99 | $42.37 |
| 52-Week LowLowest price in past year | $2.43 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +53.0% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 52.9 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 872K | 1.8M |
RARE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LXEO as "Buy" and RARE as "Buy". Consensus price targets imply 217.9% upside for LXEO (target: $19) vs 97.1% for RARE (target: $52).
| Metric | LXEOLexeo Therapeutic… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $18.50 | $51.50 |
| # AnalystsCovering analysts | 5 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). LXEO leads in 2 (Income & Cash Flow, Total Returns).
Best OverallUltragenyx Pharmaceutical I… (RARE)Leads 3 of 6 categories
Loading custom metrics...
LXEO vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LXEO or RARE a better buy right now?
Analysts rate Lexeo Therapeutics, Inc.
Common Stock (LXEO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LXEO or RARE?
Over the past 5 years, Lexeo Therapeutics, Inc.
Common Stock (LXEO) delivered a total return of -42. 1%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: LXEO returned -42. 1% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LXEO or RARE?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.
(RARE) is the lower-risk stock at 1. 42β versus Lexeo Therapeutics, Inc. Common Stock's 1. 98β — meaning LXEO is approximately 40% more volatile than RARE relative to the S&P 500.
04Which is growing faster — LXEO or RARE?
On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc.
grew EPS 7. 3% year-over-year, compared to -24. 1% for Lexeo Therapeutics, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LXEO or RARE?
Lexeo Therapeutics, Inc.
Common Stock (LXEO) is the more profitable company, earning 0. 0% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LXEO leads at 0. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LXEO or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LXEO or RARE better for a retirement portfolio?
For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Lexeo Therapeutics, Inc. Common Stock (LXEO) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, LXEO: -42. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LXEO and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LXEO is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.